Merck & Co., Inc. (MRK) Release: Study Showed VYTORIN Superior To Lipitor At Lowering LDL Cholesterol
10/19/2005 5:12:56 PM
Results from a clinical trial conducted in 1,902 patients with high cholesterol showed that VYTORIN(TM) (ezetimibe/simvastatin) provided greater reduction in LDL ("bad") cholesterol across the dosing ranges compared to Lipitor. At the most commonly used starting doses of these two therapies, VYTORIN 10/20 mg decreased LDL cholesterol by 51 percent compared with 36 percent for Lipitor 10 mg (p<0.001). The results were presented today at the American College of Cardiology's 2005 Annual Scientific Session.
comments powered by